Pharmaceuticals

Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron and Others) - Global Opportunities and Forecast 2014-2022

  • ALL905684
  • 70 Pages
  • January 2017
  • Pharmaceuticals
Download Sample    Get Discount   
 

Nausea and vomiting is one of the common side effects of chemotherapy in the cancer patients. Because of such side effects the patient population either refuse or deferment the therapeutic chemotherapy treatment for cancer.

The global Chemotherapy-induced Nausea and Vomiting market was valued at $1,663 million in 2015, and is estimated to reach $2, 659 million by 2022, registering a CAGR of 7.1% during the forecast period. At present, pharmaceutical companies are increasingly investing in the further discovery of CINV drugs through focused clinical research studies. Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016 approximately 1.6 million new cases of cancer will be diagnosed with breast, lung and bronchus cancer as most common along all the types in addition to existing number of cancer patients.

The global CINV market is segmented into patient pool type and geography. The patient pool type is segmented into namely Aloxi (palonosetron), Kytril Generic (Granisetron), Emend (aprepitant), Netupitant-Palonosetron FDC and Others. Among the segments, the Netupitant Palonosetron market is expected to witness the fastest growth, globally during the forecast period 2016-2022.

Based on geography, the global CINV market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share (nearly half) in the global chemotherapy-induced nausea and vomiting market in 2015 due to growth in demand for CINV drugs due to the rise in number of patients undergoing chemotherapy, introduction of novel delivery methods to improve patient compliance. However, Asian region is expected to grow at a fastest CAGR during the forecast period, owing to large CINV patient pool and huge demand for the Netupitant‐Palonosetron from these patients. Netupitant - Palonosetron is one of the first forms of fixed dose combination, which is approved for treating chemotherapy-induced nausea and vomiting that is likely to drive this market in the near future.

KEY BENEFITS

  • The study provides in-depth analysis of the CINV market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • The study provides analysis of key market dynamics, which influence the adoption of CINV drugs
  • The report provides a quantitative analysis for the period of 2014‐2022 to enable stakeholders to capitalize on the prevailing opportunities in the industry.
  • Extensive analysis of the global market helps understand cancer inducing Nausea and vomiting drugs developed and marketed by the key companies.
  • Competitive intelligence of market players highlights the business practices and trends across various regions.

KEY MARKET SEGMENTS:

Patient Pool Type

  • Aloxi, Kytril
  • Emend
  • Netupitant-Palonosetron
  • Others

By Geography

  • North America

    • US
    • Canada
    • Mexico

  • Europe

    • Germany
    • France
    • UK
    • Rest of Europe

  • Asia-Pacific

    • China
    • Japan
    • Rest of Asia-Pacific

  • LAMEA

    • Latin America
    • Middle East
    • Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • GlaxoSmithKline plc
  • Helsinn Holding S.A.
  • Heron Therapeutics, Inc.
  • Merck & Co., Inc.
  • Tesaro, Inc

Chapter: 1 INTRODUCTION

1.1 Report Description

1.2 Key Benefits

1.3 Key Market Segments

1.4 Research Methodology

1.4.1 Secondary Research

1.4.2 Primary Research

1.4.3 Analyst Tools and Models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO Perspective

Chapter: 3 MARKET OVERVIEW

3.1 Market Definition and Scope

3.2 Key Findings

3.2.1 Top Impacting Factors

3.2.2 Top Investment Pockets

3.3 Porters Five Force Analysis

3.4 Drivers

3.4.1 Growing Number of patients undergoing Chemotherapy

3.4.2 Growing research and development efforts in order to discover a universal antiemetic therapy

3.4.3 Introduction of novel delivery methods to improve patient compliance.

3.4.4 Advancements in technology to discover new potential drug targets

3.5 Restrains

3.5.1 Increasing side effects of CINV drugs

3.5.2 High cost associated with the new drug discovery and in developing regions.

3.6 Opportunities

3.6.1 Efficacy of combination therapy is expected to improve.

3.6.2 Improved quality of life for patients with cancer.

3.7 Market Trends

Chapter: 4 CINV MARKET BY PATIENT POOL

4.1 Overview

4.2 Netupitant-Palonosetron FDC

4.2.1 Key market trends

4.2.2 Key growth factors & opportunities

4.2.3 Market size & forecasts

4.3 Aloxi (palonosetron)

4.3.1 Key market trends

4.3.2 Key growth factors & opportunities

4.3.3 Market size & forecasts

4.4 Kytril Generic (Granisetron)

4.4.1 Key market trends

4.4.2 Key growth factors & opportunities

4.4.3 Market size & forecasts

4.5 Emend (aprepitant)

4.5.1 Key market trends

4.5.2 Key growth factors & opportunities

4.5.3 Market size & forecasts

Chapter: 5 CINV MARKET BY GEOGRAPHY

5.1 North America

5.1.1 Key Market Trends

5.1.2 Key Growth Factors and Opportunities

5.1.3 Market Size and Forecast

5.2 Europe

5.2.1 Key Market Trends

5.2.2 Key Growth Factors and Opportunities

5.2.3 Market Size and Forecast

5.3 Asia-Pacific

5.3.1 Key Market Trends

5.3.2 Key Growth Factors and Opportunities

5.3.3 Market Size and Forecast

5.4 Latin America, Middle East and Africa (LAMEA)

5.4.1 Key Market Trends

5.4.2 Key Growth Factors and Opportunities

5.4.3 Market Size and Forecast

Chapter: 6 COMPANY PROFILES

6.1 Helsinn Holding S.A.

6.1.1 Company Overview

6.1.2 Key Strategies and Developments

6.1.3 SWOT Analysis

6.2 Heron Therapeutics, Inc.

6.2.1 Company Overview

6.2.2 Business Performance

6.2.3 Key Strategies and Developments

6.2.4 SWOT Analysis

6.3 Merck & Co., Inc

6.3.1 Company Overview

6.3.2 Business Performance

6.3.3 Key Strategies and Developments

6.3.4 SWOT Analysis

6.4 GlaxoSmithKline plc

6.4.1 Company Overview

6.4.2 Business Performance

6.4.3 Key Strategies and Developments

6.4.4 Key Strategies and Developments

6.4.5 SWOT Analysis

6.5 Cadila Pharmaceuticals Limited

6.5.1 Company Overview

6.5.2 Business Performance

6.5.3 Key Strategies and Developments

6.5.4 Key Strategies and Developments

6.5.5 SWOT Analysis

6.6 Amneal Pharmaceuticals

6.6.1 Company Overview

6.6.2 Business Performance

6.6.3 Key Strategies and Developments

6.6.4 Key Strategies and Developments

6.6.5 SWOT Analysis

6.7 Kyowa Kirin, Inc.

6.7.1 Company Overview

6.7.2 Business Performance

6.7.3 Key Strategies and Developments

6.7.4 Key Strategies and Developments

6.7.5 SWOT Analysis

6.8 Acacia Pharma

6.8.1 Company Overview

6.8.2 Business Performance

6.8.3 Key Strategies and Developments

6.8.4 Key Strategies and Developments

6.8.5 SWOT Analysis

6.9 Insys Therapeutics, Inc

6.9.1 Company Overview

6.9.2 Business Performance

6.9.3 Key Strategies and Developments

6.9.4 Key Strategies and Developments

6.9.5 SWOT Analysis

6.10 Tesaro, Inc.

6.10.1 Company Overview

6.10.2 Business Performance

6.10.3 Key Strategies and Developments

6.10.4 Key Strategies and Developments

6.10.5 SWOT Analysis

*Details on financial performance, strategic moves and developments and SWOT analysis may not be captured for unlisted companies.

List of Figures

FIG. 1 TOP IMPACTING FACTORS

FIG. 2 TOP INVESTMENT POCKETS

FIG. 3 PORTERS FIVE FORCES ANALYSIS OF LITHIUM-ION BATTERY MARKET

FIG. 4 WORLD CINV MARKET BY TYPE, 2015(PIE CHART OF GLOBAL NUMBERS BY TYPE)

FIG. 5 WORLD CINV MARKET BY GEOGRAPHY, 2015(PIE CHART OF GLOBAL NUMBERS BY GEOGRAPHY)

FIG. 6 NET SALES OF HERON THERAPEUTICS, INC., 2013-2015 ($MILLION)

FIG. 7 NET SALES OF HERON THERAPEUTICS, INC., BY SEGMENT (%), 2015

FIG. 8 NET SALES OF HERON THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015

FIG. 10 NET SALES OF MERCK & CO., INC, 2013-2015 ($MILLION)

FIG. 11 NET SALES OF MERCK & CO., INC., BY GEOGRAPHY (%), 2015

FIG. 11 NET SALES OF MERCK & CO., INC., BY SEGMENT (%), 2015

FIG. 12 NET SALES OF GLAXOSMITHKLINE PLC ., 2013-2015 ($MILLION)

FIG. 13 NET SALES OF GLAXOSMITHKLINE PLC, BY SEGMENT (%), 2015

FIG. 14 NET SALES OF GLAXOSMITHKLINE PLC, BY GEOGRAPHY (%), 2015

FIG. 18 NET SALES OF KYOWA KIRIN, INC., 2013-2015 ($MILLION)

FIG. 13 NET SALES OF KYOWA KIRIN, INC., BY SEGMENT (%), 2015

FIG. 14 NET SALES OF KYOWA KIRIN, INC., BY GEOGRAPHY (%), 2015

FIG. 22 REVENUE OF INSYS THERAPEUTICS, INC., 2013-2015 ($MILLION)

FIG. 13 NET SALES OF INSYS THERAPEUTICS, INC., BY SEGMENT (%), 2015

FIG. 14 NET SALES OF INSYS THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015

FIG. 22 REVENUE OF TESARO, INC, 2013-2015 ($MILLION)

FIG. 13 NET SALES OF TESARO, INC, BY SEGMENT (%), 2015

FIG. 14 NET SALES OF TESARO, INC, BY GEOGRAPHY (%), 2015

List of Tables

TABLE 1 WORLD CINV MARKET BY PATIENT POOL(NETUPITANT-PALONOSETRON FDC) MARKET, ($MILLION), GROWTH (%)2014-2022

TABLE 2 WORLD CINV MARKET BY PATIENT POOL( ALOXI) , ($MILLION), GROWTH (%)2014-2022

TABLE 3 WORLD CINV MARKET BY PATIENT POOL(KYTRIL GENERIC ) , ($MILLION), GROWTH (%)2014-2022

TABLE 4 WORLD CINV MARKET BY PATIENT POOL(EMEND ) , ($MILLION), GROWTH (%)2014-2022

TABLE 5 NORTH AMERICA CINV MARKET, ($MILLION), GROWTH (%)2014-2022

TABLE 6 EUROPE CINV MARKET, ($MILLION), GROWTH (%)2014-2022

TABLE 7 ASIA CINV MARKET, ($MILLION), GROWTH (%)2014-2022

TABLE 8 LAMEA CINV MARKET, ($MILLION), GROWTH (%)2014-2022

TABLE 9 HELSINN HOLDING S.A.COMPANY SNAPSHOT

TABLE 9 HELSINN HOLDING S.A.OPERATING SEGMENTS

TABLE 10 HERON THERAPEUTICS, INC. COMPANY SNAPSHOT

TABLE 11 HERON THERAPEUTICS, INC.OPERATING SEGMENTS

TABLE 12 MERCK & CO., INC. COMPANY SNAPSHOT

TABLE 13 MERCK & CO., INC.OPERATING SEGMENTS

TABLE 14 GLAXOSMITHKLINE PLC COMPANY SNAPSHOT

TABLE 15 GLAXOSMITHKLINE PLC OPERATING SEGMENTS

TABLE 16 CADILA PHARMACEUTICALS LIMITED COMPANY SNAPSHOT

TABLE 17 CADILA PHARMACEUTICALS LIMITED OPERATING SEGMENTS

TABLE 18 AMNEAL PHARMACEUTICALS COMPANY SNAPSHOT

TABLE 19 AMNEAL PHARMACEUTICALS OPERATING SEGMENTS

TABLE 20 KYOWA KIRIN, INC. COMPANY SNAPSHOT

TABLE 21 KYOWA KIRIN, INC. OPERATING SEGMENTS

TABLE 22 ACACIA PHARMA COMPANY SNAPSHOT

TABLE 23 ACACIA PHARMA OPERATING SEGMENTS

TABLE 24 INSYS THERAPEUTICS, INC. COMPANY SNAPSHOT

TABLE 25 INSYS THERAPEUTICS, INC. OPERATING SEGMENTS

TABLE 26 TESARO, INC. COMPANY SNAPSHOT

TABLE 27 TESARO, INC. OPERATING SEGMENTS

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Similar Reports

Protein Therapeutics Market by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone) and Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...

  • Publish Date: November 14, 2017
  • $5370
Global Cord Blood Banking Services (Stem Cell) Market, Size, Share, Trends, Forecast, Global Analysis, Research, Report, Segmentation, and Future Demand, 2012 - 2020

Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...

  • Publish Date: July 20, 2017
  • $5370